<DOC>
	<DOC>NCT00272740</DOC>
	<brief_summary>The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate</brief_summary>
	<brief_title>SAKK - a Trial to Evaluate Antitumor Efficacy of FaslodexÂ® After Aromatase Inhibitor Failure in Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histological/cytological confirmation of breast cancer progression under treatment with an aromatase inhibitor At least one measurable or nonmeasurable lesion Prior treatment for breast cancer with more than 2 different hormonal agents More than 1 chemotherapy for advanced disease Presence of lifethreatening metastatic visceral disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>hormonotherapy</keyword>
	<keyword>aromatase inhibitor failure</keyword>
	<keyword>Advanced breast cancer</keyword>
</DOC>